

PMS, PMDD Can Be Considered on a Continuum

BY GREG MUIRHEAD
Contributing Writer

KOLOA, HAWAII — The DSM-IV criteria for diagnosing premenstrual dysphoric disorder need to be improved, Dr. Meir Steiner said at the annual meeting of the American College of Psychiatrists.

“What is wrong with the DSM criteria for PMDD?” he asked rhetorically. All the questions listed have just yes-or-no answers, indicating that the criteria are too rigid. As a result, in the 17 years since the DSM criteria were formed, the Food and Drug Administration has not allowed “any

studies on PMS because they claim there are no criteria that define or identify PMS,” he said.

“I believe PMS and PMDD are on a spectrum. PMDD is primarily what we psychiatrists are dealing with, which are primarily the mood syndromes, whereas PMS is something [obstetricians and gynecologists] see more of, which are primarily physical symptoms,” said Dr. Steiner, professor of psychiatry and behavioral neurosciences, and ob.gyn. at McMaster University in Hamilton, Ont.

Dr. Steiner and his colleagues decided to try assessing DSM-IV criteria on a spec-

trum. With this approach, the physician would look at the symptom irritability, for example, and ask patients, “Is it severe, is it moderate, is it mild, or does it not exist at all?”

“By doing that, you have actually taken the DSM-IV criteria and transformed them from a yes/no to a continuum,” he said. (See box.) They did the same with the DSM-IV questions regarding the burden of illness.

The investigators then created the following formula: If at least one of the first four criteria is severe (which is what the DSM-IV requires); at least four of the questions from 1 to 14 is moderate to severe; and at least one of the burden criteria is severe, then a patient qualifies for PMDD. Then they went a step further: “If you are missing one step on each of these [criteria], you will still qualify for what we have identified as severe PMS,” he said.

They tested their new instrument on women who were at least 18 years of age, asking them to fill out a questionnaire that listed the 14 DSM-IV criteria for PMDD and to rate their symptoms as “not at all,” “mild,” “moderate,” or “severe.” A total of 5.1% of women qualified as having PMDD, and 20.7% had severe PMS.

To fulfill the diagnosis of PMS, “they had the burden of illness and they had symptoms of PMDD, but were short one severity criterion,” said Dr. Steiner, who is also founding director of the Women’s Health Concerns Clinic for St. Joseph’s Healthcare in Hamilton.

Because the FDA was not convinced that these symptoms occurred in girls younger than 18 years of age, Dr. Steiner and his associates tried the questionnaire on girls aged 12-17 years. They interviewed 604 girls from three high

Diagnostic Criteria for PMDD

A. Symptoms must occur during the week before menses and remit a few days after onset of menses. Five of the following symptoms must be present and at least one must be 1, 2, 3, or 4.

1. Depressed mood or dysphoria.
2. Anxiety or tension.
3. Affective lability.
4. Irritability.
5. Decreased interest in usual activities.
6. Concentration difficulties.
7. Marked lack of energy.
8. Marked change in appetite, overeating, or food cravings.
9. Hypersomnia or insomnia.
10. Feeling overwhelmed.
11. Other physical symptoms, such as breast tenderness or bloating.

B. Symptoms must interfere with work, school, usual activities, or relationships.

C. Symptoms must not be merely an exacerbation of another disorder.

D. Criteria A, B, and C must be confirmed by prospective daily ratings for at least two consecutive symptomatic menstrual cycles.

Source: DSM-IV, Text Revision

Premenstrual Symptoms Questionnaire

1. Anger/irritability.
2. Anxiety/tension.
3. Tearful/increased sensitivity to rejection.
4. Depressed mood/hopelessness.
5. Decreased interest in work activities.
6. Decreased interest in home activities.
7. Decreased interest in social activities.
8. Difficulty concentrating.
9. Fatigue/lack of energy.
10. Overeating/food cravings.
11. Insomnia.
12. Hypersomnia.
13. Feeling overwhelmed or out of control.
14. Physical symptoms: breast tenderness, headaches, joint/muscle pain, bloating, weight gain.

Source: Dr. Steiner



Ob.Gyn. News®

PRESENTS AN EDUCATIONAL SUPPLEMENT

Clinical Perspectives in Intrauterine Contraception and Postmenopausal Hormone Therapy

HIGHLIGHTS OF SYMPOSIA

FEATURING:

James A. Simon, MD, CCD, FACOG
Philip D. Darney, MD, MSc
Jeffrey T. Jensen, MD, MPH

THIS SUPPLEMENT WAS SUPPORTED BY:



THIS SUPPLEMENT IS AVAILABLE AT
www.obgynnews.com/content/cmelibrary

Emergency Contraception Visit Seen As Prime Time for STD Screening

BY MICHELE G. SULLIVAN
Mid-Atlantic Bureau

CHICAGO — Only 27% of women requesting emergency contraception received screening for chlamydia and gonorrhea, and of those who were screened, 12% were positive for at least one infection, according to the findings of a study conducted in 10 New York City-based sexual health clinics.

“Emergency contraception [EC] visits represent an important opportunity to improve STD testing and treatment. ... Screening more women who request emergency contraception should be a high priority,” said the study’s lead investigator, Shoshanna Handel, a public health official with the Centers for Disease Control and Prevention and the New York City Department of Health and Mental Hygiene.

Clinic visit data from a 19-month period were analyzed. A total of 3,758 women made 4,657 requests for EC. For 66% of these women, EC was the main reason for the visit, Ms. Handel said at a conference on STD prevention sponsored by the CDC.

schools. Of those girls, 9% qualified as having PMDD and 31% had severe PMS. Of the latter, “what was missing was the burden of illness,” he said, noting that “four of the girls eventually came to the clinic for treatment.” ■

The patients’ median age was 21 years, but 12% of the requests came from women under 18 years, who are unable to buy EC without a prescription. More than 75% of the requests came from women aged 25 years and under, precisely the group for which the CDC recommends annual chlamydia and gonorrhea screening. Overall, 27% of the EC visits included testing; 11% of these patients tested positive for chlamydia and 2% for gonorrhea. Women aged 25 and younger were significantly more likely to test positive (14% vs. 7%).

When the visits were separated into EC-only requests and visits comprising EC and other services, there was a significant difference in how often screening was offered. “At the EC-only visits, 4% of women were screened. But at the EC-plus visits, 71% were screened,” Ms. Handel said.

After reviewing the analysis, the New York City STD clinics changed their screening policy for women seeking EC. “Our previous protocol stressed expedited EC access. Now we offer chlamydia and gonorrhea screening as a package with emergency contraception,” she said. ■